US Senators Introduce Bill to Reform 340B Drug Program

• A bipartisan group of six senators introduced a bill to reform the 340B drug program.
• The legislation aims to lock in hospitals' use of contract pharmacies and introduce new transparency and compliance rules.
• The bill would establish a national data clearinghouse to identify and prevent duplicate discounts.

The introduction of this legislation is significant because it has the potential to impact how hospitals manage their 340B programs, including their use of contract pharmacies and management of duplicate discounts.

A bipartisan group of six US senators has introduced a bill to reform the 340B drug program. The legislation aims to lock in hospitals' use of contract pharmacies and introduce new transparency and compliance rules. This move comes as a response to the Department of Health and Human Services (HHS) rebate pilot, which has been met with resistance from lawmakers.

The bill would also establish a national data clearinghouse to identify and prevent duplicate discounts, a key issue in the 340B program. Duplicate discounts occur when pharmacies claim rebates for the same prescription, resulting in lost revenue for hospitals.

The 340B drug program is a federal initiative that requires pharmaceutical manufacturers to provide discounted medications to eligible healthcare providers. In exchange, these providers are expected to use the savings to improve patient care and services. However, the program has faced criticism for its lack of transparency and accountability, leading to concerns about duplicate discounts and improper use of contract pharmacies.

The HHS rebate pilot was introduced in an effort to address some of these issues, but it has been met with opposition from lawmakers who argue that it would harm hospitals' ability to provide care to vulnerable populations. The new bill aims to address these concerns by introducing new transparency and compliance rules.

The introduction of this legislation is significant because it has the potential to impact how hospitals manage their 340B programs, including their use of contract pharmacies and management of duplicate discounts. Lawyers advising hospitals on 340B compliance should be aware of these changes and consider how they may affect their clients' operations.

Furthermore, the bill's focus on transparency and accountability is a step in the right direction for the 340B program. By addressing issues such as duplicate discounts and improper use of contract pharmacies, lawmakers can help ensure that the program is working as intended to improve patient care and services.

Lawyers advising hospitals on 340B compliance should watch for the introduction of new transparency and compliance rules, which may impact their use of contract pharmacies and management of duplicate discounts.

Source: Original reporting via Above the Law